Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.410
-0.080 (-1.78%)
At close: May 4, 2026, 4:00 PM EDT
4.500
+0.090 (2.04%)
After-hours: May 4, 2026, 7:59 PM EDT
Nuvation Bio Employees
Nuvation Bio had 298 employees as of December 31, 2025. The number of employees increased by 78 or 35.45% compared to the previous year.
Employees
298
Change (1Y)
78
Growth (1Y)
35.45%
Revenue / Employee
$480,020
Profits / Employee
-$489,913
Market Cap
1.53B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Immatics | 711 |
| Immunocore Holdings | 524 |
| Biohaven | 274 |
| Viridian Therapeutics | 252 |
| Precigen | 160 |
| Monte Rosa Therapeutics | 150 |
| Maze Therapeutics | 141 |
NUVB News
- 9 hours ago - Nuvation Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 9 hours ago - Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update - PRNewsWire
- 7 days ago - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - PRNewsWire
- 13 days ago - Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 - PRNewsWire
- 14 days ago - Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 - PRNewsWire
- 4 weeks ago - Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo - PRNewsWire
- 5 weeks ago - Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency - PRNewsWire
- 6 weeks ago - NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm - Business Wire